Sugi Predict

Sugi Predict / Compounds / SCHEMBL1300747

SCHEMBL1300747

SCHEMBL1300747

CC1(C)OC[C@H]([C@@H]2OC(=O)[C@H](O)[C@@H]2O)O1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 5/20 0.38
▸ CA1 P00915 4/20 0.38
▸ MGAM O43451 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ SI P14410 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ MGAM2 Q2M2H8 1/20 0.38
▸ CA9 Q16790 1/20 0.35
▸ LMNA P02545 2/20 0.33
▸ GBA1 P04062 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ DNMT1 P26358 1/20 0.30
▸ CTDSP1 Q9GZU7 1/20 0.30
▸ MANBA O00462 1/20 0.30
▸ IDUA P35475 1/20 0.30
▸ THRB P10828 1/20 0.30
▸ HIF1A Q16665 1/20 0.30
▸ GUSB P08236 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11628264 1.00 CA2 (0.38) CA2CA1MGAMGAASI
SCHEMBL7150853 1.00 CA2 (0.38) CA2CA1MGAMGAASI
SCHEMBL14341554 1.00 CA2 (0.38) CA2CA1MGAMGAASI
SCHEMBL13482823 1.00 CA2 (0.38) CA2CA1MGAMGAASI
SCHEMBL12103336 1.00 CA2 (0.38) CA2CA1MGAMGAASI
SCHEMBL1738813 1.00 CA2 (0.38) CA2CA1MGAMGAASI
SCHEMBL4105283 0.91 CA2 (0.41) CA2CA1MGAMGAASI
SCHEMBL7154387 0.87 CA2 (0.41) CA2CA1MGAMGAASI
SCHEMBL9126513 0.84 CA2 (0.40) CA2CA1MGAMGAASI
SCHEMBL14010732 0.84 CA2 (0.40) CA2CA1MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-08-25 — — US disclosed
EP-1732931-B1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL JANSSEN SCIENCES IRELAND UC (IE) 2016-05-18 — — EP disclosed
EP-2522367-B1 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2016-01-20 — — EP disclosed
US-9107956-B2 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2015-08-18 — — US disclosed
EP-2131865-B1 OLIGOMER-PROTEASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2014-12-17 — — EP disclosed
US-20140045770-A1 OLIGOMER-PROTEASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-13 — — US disclosed
US-8598364-B2 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2013-12-03 — — US disclosed
EP-2522367-A1 Oligomer-protease inhibitor conjugates Nektar Therapeutics (US) 2012-11-14 — — EP disclosed
US-20110269677-A1 Oligomer-Protease Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2011-11-03 — — US disclosed
US-20100184989-A1 De Novo Synthesis of Conjugates NEKTAR THERAPEUTICS (US) 2010-07-22 — — US disclosed
US-7595408-B2 Methods for the preparation of (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol TIBOTEC PHARMACEUTICALS, LTD. (IE) 2009-09-29 — — US disclosed
US-20070208184-A1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL Janssen Sciences Ireland Unlimited Company (IE) 2007-09-06 — — US disclosed
EP-1732931-A1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL Tibotec Pharmaceuticals Ltd. (IE) 2006-12-20 — — EP disclosed
US-7126015-B2 Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol TIBOTEC PHARMACEUTICALS LTD. (IE) 2006-10-24 — — US disclosed
WO-2005095410-A1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-10-13 — — WO disclosed
US-20040249175-A1 Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol Janssen Sciences Ireland Unlimited Company (IE) 2004-12-09 — — US disclosed
EP-1448567-A1 METHOD FOR THE PREPARATION OF HEXAHYDRO-FURO 2,3-B]FURAN-3-OL Tibotec Pharmaceuticals Ltd. (IE) 2004-08-25 — — EP disclosed
WO-2003022853-A1 METHOD FOR THE PREPARATION OF HEXAHYDRO-FURO[2,3-B]FURAN-3-OL TIBOTEC PHARMACEUTICALS LTD. (IE) 2003-03-20 — — WO disclosed
EP-0000092-A1 Method of preparing ascorbic acid and intermediates specially adapted for use therein PFIZER INC. (US) 1978-12-20 — — EP disclosed
US-4111958-A Ascorbic acid synthesis PFIZER INC. (US) 1978-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS TYMP, NME1, PNP CA2 4481/4885CA1 3914/4885MGAM 1809/4885
US-20070208184-A1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL HTR3C, UGT1A3, HTR3D CA2 3199/4885CA1 1697/4885MGAM 1410/4885
US-20100184989-A1 De Novo Synthesis of Conjugates ABCG2, UGT1A8, SLC7A5 CA2 4454/4885CA1 2289/4885MGAM 917/4885
US-20040249175-A1 Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol HAAO, BBOX1, FBP1 CA2 3618/4885CA1 3347/4885MGAM 595/4885
US-20140045770-A1 OLIGOMER-PROTEASE INHIBITOR CONJUGATES DNPEP, ADAM17, SERPINB1 CA2 2500/4885CA1 851/4885MGAM 350/4885
US-20110269677-A1 Oligomer-Protease Inhibitor Conjugates ADAM17, DNPEP, SERPINB1 CA2 2356/4885CA1 567/4885MGAM 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback